- Home
- NVCR
NVCR
NovoCure Limited
as 11-21-2024 11:37am EST
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
| Founded: | 2000 | Country: | Jersey |
| Employees: | N/A | City: | ST. HELIER |
| Market Cap: | 1.8B | IPO Year: | 2015 |
| Target Price: | $26.60 | AVG Volume (30 days): | 885.1K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.29 - $24.74 | Next Earning Date: | 10-30-2024 |
| Revenue: | $577,738,000 | Revenue Growth: | 14.63% |
| Revenue Growth (this year): | 19.13% | Revenue Growth (next year): | 5.33% |
Stock Insider Trading Activity of NovoCure Limited (NVCR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Paravasthu Mukund | NVCR | Chief Operating Officer | Nov 2 '24 | Sell | $16.69 | 44 | $734.18 | 3,459 | |
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Nov 1 '24 | Sell | $15.94 | 598 | $9,530.74 | 161,236 | |
| Paravasthu Mukund | NVCR | Chief Operating Officer | Nov 1 '24 | Sell | $15.88 | 160 | $2,540.42 | 3,459 | |
| Puri Michal Nath | NVCR | Chief Human Resources Officer | Oct 31 '24 | Sell | $15.79 | 810 | $12,791.68 | 110,093 |
Latest NovoCure Limited News
NVCR Breaking Stock News: Dive into NVCR Ticker-Specific Updates for Smart Investing
MT Newswires
4 hours ago
NovoCure Gets FDA Nod for Updated Optune Gio Arrays
Business Wire
5 hours ago
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
Business Wire
5 hours ago
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
TipRanks
21 days ago
NovoCure’s Strong Q3 and Leadership Changes in 2024
GuruFocus.com
21 days ago
NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...
Motley Fool
22 days ago
NovoCure (NVCR) Q3 2024 Earnings Call Transcript
MT Newswires
22 days ago
NovoCure Names New Chief Financial Officer
MT Newswires
22 days ago
NovoCure Q3 Loss Narrows, Net Revenue Increases
Compare NVCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVCR NovoCure Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.